HomeNewsPodcastCoronavirus Essential podcast | Will India get access to the Pfizer vaccine? Brazil halts Chinese vaccine trials after adverse effects on volunteer

Coronavirus Essential podcast | Will India get access to the Pfizer vaccine? Brazil halts Chinese vaccine trials after adverse effects on volunteer

Tune into Coronavirus Essential podcast for all the top news on the pandemic.

Moneycontrol News
November 10, 2020 / 19:10 IST
Story continues below Advertisement
Remove Ad

On November 9, the US drug major Pfizer and German biotech firm BioNTech announced that their COVID-19 vaccine candidate is more than 90 percent effective, and the pharma company said it expects to globally produce up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021. However, human rights organisation Amnesty International has warned that richer countries are already hoarding the vaccine candidate.

Story continues below Advertisement
Remove Ad

Meanwhile, Brazil on November 10 said it had stopped testing the vaccine, being developed by Sinovac Biotech after one of its volunteers suffered “serious adverse effects.”

Tune in to Coronavirus Essential with Sakshi Batra for all the top news on the pandemic.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
 View more
+ Show
Moneycontrol News
first published: Nov 10, 2020 07:10 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.